RAND's divisions conduct research on a uniquely broad front for clients around the globe.
Most relevant regions
Research
Mar 11, 2026
Colorectal cancer screening progress, boosted by U.S. campaigns and new blood tests, still face key challenges. Without timely follow-up, improved uptake provides no real health benefit.
Feb 25, 2026
We describe version 3.0 of CRC-SPIN, which adds new information about the serrated pathway and CRC risk in adults under 50, then estimate the effectiveness of decennial colonoscopy from 45 to 75 years old.
Sep 8, 2025
The objective of this paper is to determine the outcomes and cost-effectiveness of providing a rideshare intervention to patients with abnormal fecal immunochemical test results.
Aug 8, 2025
Using the CRC-SPIN microsimulation model, we show that CRC screening in the U.S. achieves three goals: it prevents 24 deaths per 1,000 Black Americans, saves tax dollars by shifting costs from Medicare to private payers, and reduces racial incidence and mortality disparities.
Jun 30, 2025
Assesses the cost-effectiveness of age- and sex-stratified colorectal cancer screening strategies.
May 2, 2025
Evaluates the robustness of colorectal cancer screening strategies, providing evidence that screening initiation at age 45 remained an efficient strategy to save life-years using fewer colonoscopies.
Jan 21, 2025
This paper evaluates the cost-effectiveness of and outcomes associated with noninvasive colorectal cancer screening strategies, including new blood-based tests, in a population with low adherence to screening.
Dec 30, 2024
We analyzed incidence rates of rectal, distal colon, and proximal colon cancer for individuals aged 20 years or more for diagnosis years 1978-2017 using 2-stage generalized linear models to determine age, period, and cohort effects for CRC incidence.
Jun 17, 2024
Identifies test performance and cost benchmarks that would make blood-based colorectal cancer screening as effective and cost-effective as established alternatives.
This paper demonstrates the use of artificial neural network emulators to enable Bayesian calibration of cancer microsimulation models.
Mar 28, 2024
This paper investigates whether novel blood-based biomarker tests that meet the current CMS coverage decision are cost-effective for colorectal cancer screening.
The American Gastroenterological Association convened a workshop to summarize the evidence on emerging blood tests for CRC screening. This paper reports those findings and provides consensus statements from the workshop's expert panel.
